Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

206.46USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$206.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,190,348
52-wk High
$208.81
52-wk Low
$163.31

Select another date:

Fri, Sep 7 2018

UPDATE 1-AstraZeneca gets FDA breakthrough therapy label for asthma treatment

Sept 7 AstraZeneca Plc and Amgen Inc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for their drug to treat a type of severe asthma, potentially speeding up its development and regulatory review.

Amgen profit beats Street view, will not raise prices again in 2018

Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

UPDATE 2-Amgen profit beats Street view, will not raise prices again in 2018

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Amgen CEO says will not raise drug prices again this year

Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

Amgen CEO says will not raise drug prices again this year

July 26 Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

Amgen quarterly profit beats Wall Street view on new product sales

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year forecast, as growth of newer drugs like cholesterol fighter Repatha and osteoporosis drug Prolia offset weakness in older products.

RPT-FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

Amgen's new migraine drug hits insurance hurdles

Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

BRIEF-Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™

* AMGEN AND NOVARTIS PRESENT NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG™ (ERENUMAB-AOOE) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE

Select another date: